Catalyst Wire Dossier Catalyst Wire Dossier

Umbilical Cord Blood-Derived Natural Killer Cells

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Umbilical Cord Blood-Derived Natural Killer Cells, covering 2025-05-09 to 2025-05-09. Get the full timeline:

Most recent: Clinical Trial Update: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]

See pricing